SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 42.90 |
| Enterprise Value ($M) | 70.25 |
| Book Value ($M) | 95.23 |
| Book Value / Share | 4.40 |
| Price / Book | 0.45 |
| NCAV ($M) | 9.70 |
| NCAV / Share | 0.45 |
| Price / NCAV | 4.42 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.31 |
| Return on Assets (ROA) | -0.28 |
| Return on Equity (ROE) | -0.30 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.30 |
| Current Ratio | 3.30 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18.68 |
| Assets | 104.22 |
| Liabilities | 8.98 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | University Of Texas/texas Am Investment Managment Co | 4.40 | -47.00 | |
| 13D/A | Satter Muneer A | 4.90 | -18.34 | |
| 13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 889 | 15,312 | 5.81 | |
| 1,287 | 12,719 | 10.12 | |
| 6,576 | 50,141 | 13.12 | |
| 8,773 | 31,163 | 28.15 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RGLS – Regulus Therapeutics Inc. | RMTI – Rockwell Medical, Inc. |
| RNAZ – TransCode Therapeutics, Inc. | RNXT – RenovoRx, Inc. |
| RVPH – Reviva Pharmaceuticals Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io